U.S. study shows COVID-19 vaccines are not effective against Omicron Variant without a booster

U.S. study shows COVID-19 vaccines are not effective against Omicron Variant without a booster. 

Three U.S.-authorized COVID-19 vaccines are found to be less effective against the recently discovered Omicron coronavirus variant in lab tests. 

However, an additional dose could restore most of the protection, according to a study published on Tuesday.

This study by researchers from Massachusetts General Hospital (MGH), Harvard, and MIT hasn’t yet been examined by a peer-reviewed panel of those. 

They were given the Moderna, Johnson & Johnson, and Pfizer, BioNTech vaccines against the pseudovirus engineered to look like Omicron. Omicron variant.

READ MORE: Arizona seeks U.S. Supreme Court to let abortion restrictions be imposed.

Researchers discovered “low to no” neutralization of the antibody variant of the standard regimens of the three vaccines. 

Two doses of the Moderna or Pfizer/BioNTech vaccinations or one shot of J&J’s single-dose vaccine.

However, the blood of recent recipients of a booster dose showed an effective neutralization for the variant the study concluded.

Researchers also concluded that Omicron might be more infectious than other variants that are of concern, with approximately twice as infectious as the predominant Delta version, that Omicron could shortly replace.

The results are consistent with studies published recently. Researchers from the Oxford’s University of Oxford said on Monday. 

They discovered that the two-dose Pfizer and AstraZeneca COVID-19 regimens failed to produce enough neutralizing antibodies to the new variant.

BioNTech, along with Pfizer, has announced that a three-shot regimen of COVID-19 vaccine has been capable of neutralizing the brand Omicron variant. Omicron variation in a laboratory test. 

However, two doses produced substantially less neutralizing antibodies.

Moderna, along with J&J, has yet to publish any data regarding how their vaccines perform against the new strain. 

J&J did not make a statement on the new study, and Moderna has not responded to requests for comments.